Deciphering bone marrow engraftment after allogeneic stem cell transplantation in humans using single-cell analyses
BACKGROUNDDonor cell engraftment is a prerequisite of successful allogeneic hematopoietic stem cell transplantation. Based on peripheral blood analyses, it is characterized by early myeloid recovery and T and B cell lymphopenia. However, cellular networks associated with bone marrow engraftment of allogeneic human cells have been poorly described.METHODSMass cytometry and CITE-Seq analyses were performed on bone marrow cells 3 months after transplantation in patients with acute myelogenous leukemia.RESULTSMass cytometric analyses in 26 patients and 20 healthy controls disclosed profound alterations in myeloid and B cell progenitors, with a shift toward terminal myeloid differentiation and decreased B cell progenitors. Unsupervised analysis separated recipients into 2 groups, one of them being driven by previous graft-versus-host disease (R2 patients). We then used single-cell CITE-Seq to decipher engraftment, which resolved 36 clusters, encompassing all bone marrow cellular components. Hematopoiesis in transplant recipients was sustained by committed myeloid and erythroid progenitors in a setting of monocyte-, NK cell-, and T cell-mediated inflammation. Gene expression revealed major pathways in transplant recipients, namely, TNF-α signaling via NF-κB and the IFN-γ response. The hallmark of allograft rejection was consistently found in clusters from transplant recipients, especially in R2 recipients.CONCLUSIONBone marrow cell engraftment of allogeneic donor cells is characterized by a state of emergency hematopoiesis in the setting of an allogeneic response driving inflammation.FUNDINGThis study was supported by the French National Cancer Institute (Institut National du Cancer; PLBIO19-239) and by an unrestricted research grant by Alexion Pharmaceuticals.
Authors
- Emmanuel Curis (ORCID: https://orcid.org/0000-0001-8382-1493)
- Sophie Caillat‐Zucman (ORCID: https://orcid.org/0000-0002-4535-3550)
- Marie Robin (ORCID: https://orcid.org/0000-0003-1388-9876)
- Gèrard Socié (ORCID: https://orcid.org/0000-0002-2114-7533)
- Emmanuelle Clappier (ORCID: https://orcid.org/0000-0001-7098-092X)
- Jennifer Bordenave (ORCID: https://orcid.org/0000-0001-8866-3666)
- Mathieu F. Chevalier (ORCID: https://orcid.org/0000-0002-5601-2217)
- David Michonneau (ORCID: https://orcid.org/0000-0003-4553-3065)
- Aliénor Xhaard (ORCID: https://orcid.org/0000-0002-4449-989X)
- Nicolas Vallet (ORCID: https://orcid.org/0000-0001-9568-3358)
- Flore Sicre de Fontbrune (ORCID: https://orcid.org/0000-0003-2000-1556)
- Régis Peffault de Latour (ORCID: https://orcid.org/0000-0001-6222-4753)
- Aurélien Corneau (ORCID: https://orcid.org/0000-0003-1272-6872)
- Pierre Lemaire (ORCID: https://orcid.org/0000-0002-9281-2385)
- Dorota Gajda
- Stéphanie Mathis
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Lariboisière (FR)
- Pitié-Salpêtrière Hospital (FR)
- Hôpital Saint-Louis (FR)
Publication Details
- Journal
- Journal of Clinical Investigation
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1172/jci180331
- Citations
- 7
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 3.18
Funders
- Alexion Pharmaceuticals
- Institut National Du Cancer
- National Cancer Institute